Connect your AI

4D Molecular Therapeutics FDMT Price / sales

Price / sales at other companies

Eli LillyLLY

11.4×-3.8×

Regeneron PharmaceuticalsREGN

5.5×+0.6×

Vertex PharmaceuticalsVRTX

9.3×-1.9×

EyePoint, Inc. EYPT

141.2×+135×

AbbVieABBV

6.1×-0.3×

RegenxbioRGNX

4.9×+2.6×

Other financials

Income statement

Revenue$3.0M+21,664%

Operating income-$73.6M-37.3%

Net income-$68.8M-43.3%

EPS (diluted)-$1.01-17.4%

Balance sheet

Cash & equivalents$72.5M-45.7%

Total debt$20.5M-13.9%

Total equity$451.8M-3.8%

Total assets$512.9M-0.5%

Cash flow

Operating cash flow-$68.1M-42.6%

CapEx--100%

Free cash flow-$68.1M-40.8%

Valuation

Market cap$602.22M+215%

Enterprise value$550.27M+574%

Profitability

Operating margin-220.1%-110pp

Net margin-174,314.2%-62,763pp

FCF margin-154,209.2%-53,057pp

Returns & leverage

Return on equity-45.4%+29.8pp

Debt / equity0×0.0×

Current ratio9.3×-3.0×

Where this comes from

Calculated from 4D Molecular Therapeutics’s reported figures.

market cap/total revenue=5.4×

Based on the most recent quarter.

The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about 4D Molecular Therapeutics's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is 4D Molecular Therapeutics's price / sales?: 4D Molecular Therapeutics (FDMT) reported price / sales of 5.4× in Q1 2026.
How has 4D Molecular Therapeutics's price / sales changed year-over-year?: 4D Molecular Therapeutics's price / sales decreased by 99.9% year-over-year, from 6,502.5× to 5.4×.
What is the long-term trend for 4D Molecular Therapeutics's price / sales?: Over 5 years (2020 to 2025), 4D Molecular Therapeutics's price / sales has grown at a -41.9% compound annual growth rate (CAGR), from 75.8× to 5×.
What does price / sales mean?: Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.